NCT02924402 2024-11-13Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesXencor, Inc.Phase 1 Completed154 enrolled
NCT02175433 2024-11-01A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid MalignanciesAstellas Pharma IncPhase 1 Completed71 enrolled
NCT02034110 2023-08-21Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersNovartisPhase 2 Completed206 enrolled 40 charts 2 FDA
NCT05136521 2021-11-29Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (ContramidĀ® Prolonged-release Tablets) Under Fasting ConditionsAziende Chimiche Riunite Angelini Francesco S.p.APhase 1 Completed28 enrolled
NCT01829711 2020-04-08Moxetumomab Pasudotox for Advanced Hairy Cell LeukemiaMedImmune LLCPhase 3 Completed80 enrolled 32 charts 1 FDA
NCT00586924 2019-04-02A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell LeukemiaMedImmune LLCPhase 1 Completed49 enrolled 40 charts
NCT01748721 2016-01-08MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaMorphotekPhase 1 Completed27 enrolled
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts
NCT00074048 2010-06-22BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell LeukemiaMedImmune LLCPhase 2 Completed36 enrolled